REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The trial includes up to 49 participants,…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:10 UTC
-
New drug duo shows promise for Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage study is testing whether combining two drugs—nivolumab, which helps the immune system attack cancer, and ASTX727, which targets abnormal cells—can shrink or stabilize B-cell lymphomas that have returned or stopped responding to standard treatments. About 32 adult…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
Experimental combo therapy targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests whether giving specially engineered immune cells (CAR T cells) along with a vaccine can safely treat people with intermediate or high-grade B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The CAR T cells are designed to re…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis study is for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are testing a drug called loncastuximab tesirine combined with other anti-cancer drugs to find the safest dose and see if it shrinks tumors. About 200 part…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New immune cell combo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether a new type of immune cell therapy (ONC-PluReceptor NK cells) combined with two antibody drugs (epcoritamab and tafasitamab) can help control lymphoma that has come back or not responded to prior treatments. About 30 adults aged 18-80 with specific types o…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:49 UTC